Intravenous immune globulin suppresses angiogenesis in mice and humans

Reo Yasuma; Valeria Cicatiello; Takeshi Mizutani; Laura Tudisco; Younghee Kim; Valeria Tarallo; Sasha Bogdanovich; Yoshio Hirano; Nagaraj Kerur; Shengjian Li; Tetsuhiro Yasuma; Benjamin J. Fowler; Charles B. Wright; Ivana Apicella; Adelaide Greco; Arturo Brunetti; Balamurali K. Ambati; Sevim Barbasso Helmers; Ingrid E. Lundberg; Ondrej Viklicky; Jeanette H.W. Leusen; J. Sjef Verbeek; Bradley D. Gelfand; Ana Bastos-Carvalho; Sandro De Falco; Jayakrishna Ambati

doi:10.1038/sigtrans.2015.2

Intravenous immune globulin suppresses angiogenesis in mice and humans

Reo Yasuma, Valeria Cicatiello, Takeshi Mizutani, Laura Tudisco, Younghee Kim, Valeria Tarallo, Sasha Bogdanovich, Yoshio Hirano, Nagaraj Kerur, Shengjian Li, Tetsuhiro Yasuma, Benjamin J. Fowler, Charles B. Wright, Ivana Apicella, Adelaide Greco, Arturo Brunetti, Balamurali K. Ambati, Sevim Barbasso Helmers, Ingrid E. Lundberg, Ondrej ViklickyJeanette H.W. Leusen, J. Sjef Verbeek, Bradley D. Gelfand, Ana Bastos-Carvalho, Sandro De Falco, Jayakrishna Ambati

Opthalmology

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Human intravenous immune globulin (IVIg), a purified IgG fraction composed of ~ 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG (IgG) Fc regions. Recently, we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI, a high-affinity receptor for IgG1. Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases, namely, neovascular age-related macular degeneration, corneal neovascularization, colorectal cancer, fibrosarcoma and peripheral arterial ischemic disease. Angioinhibition was mediated by the Fc region of IVIg, required FcγRI and had similar potency in transgenic mice expressing human FcγRs. Finally, IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities. These data place IVIg, an agent approved by the US Food and Drug Administration, as a novel angioinhibitory drug in doses that are currently administered in the clinical setting. In addition, they raise the possibility of an unintended effect of IVIg on blood vessels.

Original language	English
Article number	15002
Journal	Signal Transduction and Targeted Therapy
Volume	1
DOIs	https://doi.org/10.1038/sigtrans.2015.2
State	Published - 2016

Bibliographical note

Funding Information:
We thank TS Khurana, S Bondada, K Ambati, AM Rao and GS Rao for discussions; L Toll, GR Pattison R King, L Xu, M McConnell, C Payne, D Robertson, G Botzet, A Uiettenbogaard, E Lindroos and the Institute of Genetics and Biophysics animal house and integrated microscopy facilities for technical assistance. JA was supported by US National Institutes of Health (NIH) grants DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238 and R01EY024068, Doris Duke Distinguished Clinical Scientist Award, Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, Ellison Medical Foundation Senior Scholar in Aging Award, Foundation Fighting Blindness Individual Investigator Research Award, Harrington Discovery Institute Scholar-Innovator Award, Carl Marshall Reeves Foundation, John Templeton Foundation, Dr E Vernon Smith and Eloise C Smith Macular Degeneration Endowed Chair, and Research to Prevent Blindness departmental unrestricted grant; SDeF by AIRC (Associazione Italiana Ricerca sul Cancro) grant IG11420 and Italian Ministry for Scientific Research, project PON01_01434; BJF and SB by NIH T32HL091812 and UL1RR033173; YH by Alcon Research Award; AB-C by the Programme for Advanced Medical Education (sponsored by Fundação Calouste Gulbenkian, Fundação Champalimaud, Ministério da Saúde and Fundação para a Ciência e Tecnologia, Portugal) and Bayer Global Ophthalmology Research Award; YH by Alcon Japan Research award; NK by Beckman Initiative for Macular Research and NIH K99/R00EY024336; CBW by International Retinal Research Foundation; BDG by American Heart Association and International Retinal Research Foundation; BKA by NIH R01EY017182 and R01EY017950, VA Merit Award and Department of Defense; and OV by Ministry of Health, Czech Republic—conceptual development of research organization (Institute for Clinical and Experimental Medicine—IKEM, IN 00023001).

Funding Information:
JA is a co-founder of iVeena Holdings, iVeena Pharmaceuticals, iVeena Delivery Systems and Inflammasome Therapeutics, and has received honoraria from Allergan and research funding from Olix Pharmaceuticals unrelated to this work. JA and SDeF are named as inventors on patent applications filed by the University of Kentucky relating to the technology described in this work.

Publisher Copyright:
© 2016 West China Hospital, Sichuan University.

ASJC Scopus subject areas

Genetics
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sigtrans.2015.2

Cite this

Yasuma, R., Cicatiello, V., Mizutani, T., Tudisco, L., Kim, Y., Tarallo, V., Bogdanovich, S., Hirano, Y., Kerur, N., Li, S., Yasuma, T., Fowler, B. J., Wright, C. B., Apicella, I., Greco, A., Brunetti, A., Ambati, B. K., Helmers, S. B., Lundberg, I. E., ... Ambati, J. (2016). Intravenous immune globulin suppresses angiogenesis in mice and humans. Signal Transduction and Targeted Therapy, 1, [15002]. https://doi.org/10.1038/sigtrans.2015.2

@article{96e2f4b91b244b91b5603865ddb4b895,

title = "Intravenous immune globulin suppresses angiogenesis in mice and humans",

abstract = "Human intravenous immune globulin (IVIg), a purified IgG fraction composed of ~ 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG (IgG) Fc regions. Recently, we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI, a high-affinity receptor for IgG1. Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases, namely, neovascular age-related macular degeneration, corneal neovascularization, colorectal cancer, fibrosarcoma and peripheral arterial ischemic disease. Angioinhibition was mediated by the Fc region of IVIg, required FcγRI and had similar potency in transgenic mice expressing human FcγRs. Finally, IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities. These data place IVIg, an agent approved by the US Food and Drug Administration, as a novel angioinhibitory drug in doses that are currently administered in the clinical setting. In addition, they raise the possibility of an unintended effect of IVIg on blood vessels.",

author = "Reo Yasuma and Valeria Cicatiello and Takeshi Mizutani and Laura Tudisco and Younghee Kim and Valeria Tarallo and Sasha Bogdanovich and Yoshio Hirano and Nagaraj Kerur and Shengjian Li and Tetsuhiro Yasuma and Fowler, {Benjamin J.} and Wright, {Charles B.} and Ivana Apicella and Adelaide Greco and Arturo Brunetti and Ambati, {Balamurali K.} and Helmers, {Sevim Barbasso} and Lundberg, {Ingrid E.} and Ondrej Viklicky and Leusen, {Jeanette H.W.} and Verbeek, {J. Sjef} and Gelfand, {Bradley D.} and Ana Bastos-Carvalho and {De Falco}, Sandro and Jayakrishna Ambati",

note = "Funding Information: We thank TS Khurana, S Bondada, K Ambati, AM Rao and GS Rao for discussions; L Toll, GR Pattison R King, L Xu, M McConnell, C Payne, D Robertson, G Botzet, A Uiettenbogaard, E Lindroos and the Institute of Genetics and Biophysics animal house and integrated microscopy facilities for technical assistance. JA was supported by US National Institutes of Health (NIH) grants DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238 and R01EY024068, Doris Duke Distinguished Clinical Scientist Award, Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, Ellison Medical Foundation Senior Scholar in Aging Award, Foundation Fighting Blindness Individual Investigator Research Award, Harrington Discovery Institute Scholar-Innovator Award, Carl Marshall Reeves Foundation, John Templeton Foundation, Dr E Vernon Smith and Eloise C Smith Macular Degeneration Endowed Chair, and Research to Prevent Blindness departmental unrestricted grant; SDeF by AIRC (Associazione Italiana Ricerca sul Cancro) grant IG11420 and Italian Ministry for Scientific Research, project PON01_01434; BJF and SB by NIH T32HL091812 and UL1RR033173; YH by Alcon Research Award; AB-C by the Programme for Advanced Medical Education (sponsored by Funda{\c c}{\~a}o Calouste Gulbenkian, Funda{\c c}{\~a}o Champalimaud, Minist{\'e}rio da Sa{\'u}de and Funda{\c c}{\~a}o para a Ci{\^e}ncia e Tecnologia, Portugal) and Bayer Global Ophthalmology Research Award; YH by Alcon Japan Research award; NK by Beckman Initiative for Macular Research and NIH K99/R00EY024336; CBW by International Retinal Research Foundation; BDG by American Heart Association and International Retinal Research Foundation; BKA by NIH R01EY017182 and R01EY017950, VA Merit Award and Department of Defense; and OV by Ministry of Health, Czech Republic—conceptual development of research organization (Institute for Clinical and Experimental Medicine—IKEM, IN 00023001). Funding Information: JA is a co-founder of iVeena Holdings, iVeena Pharmaceuticals, iVeena Delivery Systems and Inflammasome Therapeutics, and has received honoraria from Allergan and research funding from Olix Pharmaceuticals unrelated to this work. JA and SDeF are named as inventors on patent applications filed by the University of Kentucky relating to the technology described in this work. Publisher Copyright: {\textcopyright} 2016 West China Hospital, Sichuan University.",

year = "2016",

doi = "10.1038/sigtrans.2015.2",

language = "English",

volume = "1",

}

Yasuma, R, Cicatiello, V, Mizutani, T, Tudisco, L, Kim, Y, Tarallo, V, Bogdanovich, S, Hirano, Y, Kerur, N, Li, S, Yasuma, T, Fowler, BJ, Wright, CB, Apicella, I, Greco, A, Brunetti, A, Ambati, BK, Helmers, SB, Lundberg, IE, Viklicky, O, Leusen, JHW, Verbeek, JS, Gelfand, BD, Bastos-Carvalho, A, De Falco, S & Ambati, J 2016, 'Intravenous immune globulin suppresses angiogenesis in mice and humans', Signal Transduction and Targeted Therapy, vol. 1, 15002. https://doi.org/10.1038/sigtrans.2015.2

TY - JOUR

T1 - Intravenous immune globulin suppresses angiogenesis in mice and humans

AU - Yasuma, Reo

AU - Cicatiello, Valeria

AU - Mizutani, Takeshi

AU - Tudisco, Laura

AU - Kim, Younghee

AU - Tarallo, Valeria

AU - Bogdanovich, Sasha

AU - Hirano, Yoshio

AU - Kerur, Nagaraj

AU - Li, Shengjian

AU - Yasuma, Tetsuhiro

AU - Fowler, Benjamin J.

AU - Wright, Charles B.

AU - Apicella, Ivana

AU - Greco, Adelaide

AU - Brunetti, Arturo

AU - Ambati, Balamurali K.

AU - Helmers, Sevim Barbasso

AU - Lundberg, Ingrid E.

AU - Viklicky, Ondrej

AU - Leusen, Jeanette H.W.

AU - Verbeek, J. Sjef

AU - Gelfand, Bradley D.

AU - Bastos-Carvalho, Ana

AU - De Falco, Sandro

AU - Ambati, Jayakrishna

N1 - Funding Information: We thank TS Khurana, S Bondada, K Ambati, AM Rao and GS Rao for discussions; L Toll, GR Pattison R King, L Xu, M McConnell, C Payne, D Robertson, G Botzet, A Uiettenbogaard, E Lindroos and the Institute of Genetics and Biophysics animal house and integrated microscopy facilities for technical assistance. JA was supported by US National Institutes of Health (NIH) grants DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238 and R01EY024068, Doris Duke Distinguished Clinical Scientist Award, Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, Ellison Medical Foundation Senior Scholar in Aging Award, Foundation Fighting Blindness Individual Investigator Research Award, Harrington Discovery Institute Scholar-Innovator Award, Carl Marshall Reeves Foundation, John Templeton Foundation, Dr E Vernon Smith and Eloise C Smith Macular Degeneration Endowed Chair, and Research to Prevent Blindness departmental unrestricted grant; SDeF by AIRC (Associazione Italiana Ricerca sul Cancro) grant IG11420 and Italian Ministry for Scientific Research, project PON01_01434; BJF and SB by NIH T32HL091812 and UL1RR033173; YH by Alcon Research Award; AB-C by the Programme for Advanced Medical Education (sponsored by Fundação Calouste Gulbenkian, Fundação Champalimaud, Ministério da Saúde and Fundação para a Ciência e Tecnologia, Portugal) and Bayer Global Ophthalmology Research Award; YH by Alcon Japan Research award; NK by Beckman Initiative for Macular Research and NIH K99/R00EY024336; CBW by International Retinal Research Foundation; BDG by American Heart Association and International Retinal Research Foundation; BKA by NIH R01EY017182 and R01EY017950, VA Merit Award and Department of Defense; and OV by Ministry of Health, Czech Republic—conceptual development of research organization (Institute for Clinical and Experimental Medicine—IKEM, IN 00023001). Funding Information: JA is a co-founder of iVeena Holdings, iVeena Pharmaceuticals, iVeena Delivery Systems and Inflammasome Therapeutics, and has received honoraria from Allergan and research funding from Olix Pharmaceuticals unrelated to this work. JA and SDeF are named as inventors on patent applications filed by the University of Kentucky relating to the technology described in this work. Publisher Copyright: © 2016 West China Hospital, Sichuan University.

PY - 2016

Y1 - 2016

N2 - Human intravenous immune globulin (IVIg), a purified IgG fraction composed of ~ 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG (IgG) Fc regions. Recently, we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI, a high-affinity receptor for IgG1. Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases, namely, neovascular age-related macular degeneration, corneal neovascularization, colorectal cancer, fibrosarcoma and peripheral arterial ischemic disease. Angioinhibition was mediated by the Fc region of IVIg, required FcγRI and had similar potency in transgenic mice expressing human FcγRs. Finally, IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities. These data place IVIg, an agent approved by the US Food and Drug Administration, as a novel angioinhibitory drug in doses that are currently administered in the clinical setting. In addition, they raise the possibility of an unintended effect of IVIg on blood vessels.

AB - Human intravenous immune globulin (IVIg), a purified IgG fraction composed of ~ 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG (IgG) Fc regions. Recently, we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI, a high-affinity receptor for IgG1. Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases, namely, neovascular age-related macular degeneration, corneal neovascularization, colorectal cancer, fibrosarcoma and peripheral arterial ischemic disease. Angioinhibition was mediated by the Fc region of IVIg, required FcγRI and had similar potency in transgenic mice expressing human FcγRs. Finally, IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities. These data place IVIg, an agent approved by the US Food and Drug Administration, as a novel angioinhibitory drug in doses that are currently administered in the clinical setting. In addition, they raise the possibility of an unintended effect of IVIg on blood vessels.

UR - http://www.scopus.com/inward/record.url?scp=85043614237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043614237&partnerID=8YFLogxK

U2 - 10.1038/sigtrans.2015.2

DO - 10.1038/sigtrans.2015.2

M3 - Article

AN - SCOPUS:85043614237

VL - 1

M1 - 15002

ER -

Intravenous immune globulin suppresses angiogenesis in mice and humans

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this